Hosted on MSN1mon
Precision gains CTA approval in Hong Kong for chronic hepatitis B therapy trial
in the ELIMINATE-B Phase I trial for curing chronic hepatitis B by targeting covalently closed circular DNA (cccDNA), the virus's replicative element. The company is currently recruiting subjects ...
Nature2y
A precise platform for clinical gene editing
For its wholly owned in vivo programs, Precision is developing an ARCUS nuclease that targets chronic hepatitis B covalently closed circular DNA. For its primary hyperoxaluria type 1 program ...
Nature4y
Mutation detection and single-molecule counting using isothermal rolling-circle amplification
Using a single primer, RCA generates hundreds of tandemly linked copies of a covalently closed circle in a few ... We used two different pre-formed circular DNA templates for RCA signal coding ...